Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Wuhan Keqian Biology Co's Enterprise Value is ¥3,961.9 Mil.
Wuhan Keqian Biology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was ¥324.4 Mil. Therefore, Wuhan Keqian Biology Co's EV-to-FCF for today is 12.21.
The historical rank and industry rank for Wuhan Keqian Biology Co's EV-to-FCF or its related term are showing as below:
SHSE:688526'
s EV-to-FCF Range Over the Past 10 Years
Min: 10.1 Med: 23.8 Max: 128.22
Current: 12.21
During the past 10 years, the highest EV-to-FCF of Wuhan Keqian Biology Co was 128.22. The lowest was 10.10. And the median was 23.80.
SHSE:688526's EV-to-FCF is ranked better than 54.1% of 329
companies
in the Biotechnology industry
Industry Median: 14.55
vs SHSE:688526: 12.21
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Wuhan Keqian Biology Co (SHSE:688526) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Wuhan Keqian Biology Co's PE Ratio (TTM) for today is calculated as:
Wuhan Keqian Biology Co's share price for today is ¥12.45.
Wuhan Keqian Biology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.678.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688526 vs VRTX, REGN, MRNA: EV-to-FCF Comparison
For the Biotechnology subindustry, Wuhan Keqian Biology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan Keqian Biology Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wuhan Keqian Biology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Wuhan Keqian Biology Co's EV-to-FCF falls into.
Wuhan Keqian Biology Co's current Enterprise Value is ¥3,961.9 Mil.
Wuhan Keqian Biology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥324.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan Keqian Biology Co (SHSE:688526) has a EV-to-FCF of 12.21 as of Sep. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Wuhan Keqian Biology Co and its competitors. This is 49% below median its historical median of 23.80. Over the past decade, Wuhan Keqian Biology Co's EV-to-FCF has ranged from 10.10 to 128.22. According to the industry distribution chart, Wuhan Keqian Biology Co ranks #151 out of 329 companies in the Biotechnology industry, placing it in the top 45.9%.
Is Wuhan Keqian Biology Co's EV-to-FCF too high?
Wuhan Keqian Biology Co's current EV-to-FCF of 12.21 is 49% below median its 10-year median of 23.80. Over the past 10 years, this metric has ranged from a low of 10.10 to a high of 128.22. The Biotechnology industry median EV-to-FCF is 14.55. Wuhan Keqian Biology Co's value of 12.21 is 16.1% below this industry median. Based on the distribution chart, Wuhan Keqian Biology Co ranks #151 out of 329 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Wuhan Keqian Biology Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wuhan Keqian Biology Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Wuhan Keqian Biology Co ranks #151 out of 329 companies for EV-to-FCF. This puts Wuhan Keqian Biology Co in the upper half of its industry. The industry median EV-to-FCF is 14.55. Wuhan Keqian Biology Co's value of 12.21 is 16.1% below this benchmark. Historically, Wuhan Keqian Biology Co's own EV-to-FCF has ranged from 10.10 to 128.22 over the past decade. While the company's 10-year median is 23.80 vs. the industry median of 14.55, Wuhan Keqian Biology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.55, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuhan Keqian Biology Co's current EV-to-FCF of 12.21 is 16.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Wuhan Keqian Biology Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuhan Keqian Biology Co's current EV-to-FCF is 12.21, which is 49% below median its own 10-year median of 23.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Keqian Biology Co stock overvalued right now?
Based on GuruFocus' analysis, Wuhan Keqian Biology Co (SHSE:688526) is currently considered Fairly Valued. The stock's GF Value™ is ¥13.70, compared to a current price of ¥12.45 — trading 9.1% below its estimated fair value. The current EV-to-FCF is 12.21, which is 49% below median its 10-year median of 23.80 and 16.1% below the Biotechnology industry median of 14.55. Wuhan Keqian Biology Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Wuhan Keqian Biology Co (SHSE:688526), the current EV-to-FCF is 12.21 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuhan Keqian Biology Co (SHSE:688526) Overvalued in 2026?
Based on GuruFocus' analysis, Wuhan Keqian Biology Co stock appears to be undervalued.
The current stock price of ¥12.45 is trading 9.1% below its estimated GF Value™ of ¥13.70.
GuruFocus considers Wuhan Keqian Biology Co to be Fairly Valued.
Key valuation signals for SHSE:688526:
EV-to-FCF: 12.21 (49% below median its 10-year median of 23.80)
GF Value™: ¥13.70 vs. price of ¥12.45 (9.1% below fair value)
Industry Position: 16.1% below the Biotechnology median (#151 of 329)
No single metric tells the full story. See the SHSE:688526 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuhan Keqian Biology Co Ltd is a Chinese veterinary biotechnology company engaged in the research, development, production, and sale of veterinary biological products, along with animal disease prevention and control technical services. Its core offerings are vaccines and related biologics for livestock and poultry, principally swine and avian vaccines, used by large-scale farms, breeding enterprises, and veterinary clinics across China. The company also provides diagnostic and technical support services tied to disease prevention programs. Revenue is generated mainly through the sale of veterinary vaccines and biological products, supplemented by technical service fees. Its operations and customer base are concentrated in the domestic Chinese market, where demand is driven by the scale and health management needs of the country's intensive animal husbandry sector. The company is listed on the Shanghai Stock Exchange's STAR Market.
81GF Score
Get the complete analysis for SHSE:688526
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688526 has been successfully added to your 
